EP1558609A4 - Kinase inhibitors - Google Patents

Kinase inhibitors

Info

Publication number
EP1558609A4
EP1558609A4 EP03779322A EP03779322A EP1558609A4 EP 1558609 A4 EP1558609 A4 EP 1558609A4 EP 03779322 A EP03779322 A EP 03779322A EP 03779322 A EP03779322 A EP 03779322A EP 1558609 A4 EP1558609 A4 EP 1558609A4
Authority
EP
European Patent Office
Prior art keywords
kinase inhibitors
kinase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03779322A
Other languages
German (de)
French (fr)
Other versions
EP1558609A2 (en
Inventor
George D Hartman
Jacob M Hoffman
Anthony M Smith
Thomas J Tucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1558609A2 publication Critical patent/EP1558609A2/en
Publication of EP1558609A4 publication Critical patent/EP1558609A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
EP03779322A 2002-10-30 2003-10-24 Kinase inhibitors Withdrawn EP1558609A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42231302P 2002-10-30 2002-10-30
US422313P 2002-10-30
PCT/US2003/034100 WO2004041164A2 (en) 2002-10-30 2003-10-24 Kinase inhibitors

Publications (2)

Publication Number Publication Date
EP1558609A2 EP1558609A2 (en) 2005-08-03
EP1558609A4 true EP1558609A4 (en) 2008-05-28

Family

ID=32312490

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03779322A Withdrawn EP1558609A4 (en) 2002-10-30 2003-10-24 Kinase inhibitors

Country Status (5)

Country Link
EP (1) EP1558609A4 (en)
JP (1) JP2006507302A (en)
AU (1) AU2003285007A1 (en)
CA (1) CA2503715A1 (en)
WO (1) WO2004041164A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1599468T3 (en) 2003-01-14 2008-02-04 Arena Pharm Inc 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prevention and treatment of disorders associated therewith such as diabetes and hyperglycemia
US8168568B1 (en) 2003-03-10 2012-05-01 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Combinatorial therapy for protein signaling diseases
AR045047A1 (en) * 2003-07-11 2005-10-12 Arena Pharm Inc ARILO AND HETEROARILO DERIVATIVES TRISUSTITUIDOS AS MODULATORS OF METABOLISM AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THEMSELVES
DK1756084T3 (en) * 2004-06-04 2009-03-23 Arena Pharm Inc Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prevention and treatment of disorders related thereto
AU2005314133B2 (en) 2004-12-06 2012-03-08 Medicinova, Inc. Ibudilast for treating neuropathic pain and associated syndromes
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
CA2605972C (en) 2005-04-29 2011-08-02 Ferring International Center S.A. Treatment or prevention of ovarian hyperstimulation syndrome (ohss) using a dopamine agonist
WO2006125616A2 (en) * 2005-05-25 2006-11-30 Ingenium Pharmaceuticals Ag Pyrimidine-based cdk inhibitors for treating pain
JP2009521461A (en) * 2005-12-22 2009-06-04 アイカジェン， インコーポレイテッド Calcium channel antagonist
ES2378704T3 (en) 2006-01-27 2012-04-17 Array Biopharma, Inc. Glucokinase activators
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
CN101678215B (en) 2007-04-18 2014-10-01 辉瑞产品公司 Sulfonyl amide derivatives for the treatment of abnormal cell growth
JP5566880B2 (en) 2007-04-24 2014-08-06 インゲニウム ファーマシューティカルズ ジーエムビーエイチ 4,6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
EP3078662A1 (en) 2007-09-21 2016-10-12 Array Biopharma, Inc. Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
GB0811955D0 (en) 2008-06-30 2008-07-30 Pci Biotech As Method
WO2010059384A1 (en) * 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012127032A1 (en) 2011-03-24 2012-09-27 Chemilia Ab Novel pyrimidine derivatives
EP2702043A1 (en) * 2011-04-29 2014-03-05 Exelixis, Inc. Inhibitors of inducible form of 6-phosphofructose-2-kinase
EP3242666A1 (en) 2015-01-06 2017-11-15 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
JP6838744B2 (en) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド (R) -2- (7- (4-cyclopentyl-3- (trifluoromethyl) benzyloxy) -1,2,3,4-tetrahydrocyclopenta [b] indole-for use in S1P1 receptor-related disorders Crystalline L-arginine salt of 3-yl) acetic acid (Compound 1)
TWI620748B (en) * 2016-02-05 2018-04-11 National Health Research Institutes Aminothiazole compounds and use thereof
KR20190116416A (en) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. Compounds and Methods for Treating Primary Bile Cholangitis
TWI667236B (en) * 2017-06-13 2019-08-01 財團法人國家衛生研究院 Aminothiazole compounds as protein kinase inhibitors
CN111116575B (en) * 2019-12-18 2021-06-15 浙江工业大学 5-fluoro-2, 4-pyrimidinediamine compound and preparation and application thereof
CN111388656B (en) * 2020-04-17 2021-01-15 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） Application of Kallistatin protein in preparation of medicine for preventing and treating OHSS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050071A1 (en) * 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0009721A (en) * 1999-04-15 2002-02-13 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
US20020137755A1 (en) * 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050071A1 (en) * 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases

Also Published As

Publication number Publication date
CA2503715A1 (en) 2004-05-21
WO2004041164A2 (en) 2004-05-21
AU2003285007A1 (en) 2004-06-07
EP1558609A2 (en) 2005-08-03
JP2006507302A (en) 2006-03-02
WO2004041164A3 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
EP1496910A4 (en) Kinase inhibitors
SI1569907T1 (en) Nicotinamide-based kinase inhibitors
AU2003271566A8 (en) Pyrrolopyrazines as kinase inhibitors
EG25482A (en) Inhibitors
EP1543009A4 (en) Pyrrolotriazine kinase inhibitors
AU2003249442A1 (en) Kinase inhibitors
IL165515A0 (en) Bisindolyl-maleimid derivatives as kinase inhibitors
AU2003299651A8 (en) Tyrosine kinase inhibitors
PL375352A1 (en) Azaindole kinase inhibitors
EP1558609A4 (en) Kinase inhibitors
IL173381A0 (en) 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
SI2256108T1 (en) Substituted triazine kinase inhibitors
AP2006003620A0 (en) Imidazopyrazine tyroshine kinase inhibitors
AP2048A (en) Diazepinoindole derivatives as kinase inhibitors
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
AU2003298942A8 (en) Tyrosine kinase inhibitors
AU2003245555A1 (en) Sphingosine kinase inhibitors
EP1534268A4 (en) Tyrosine kinase inhibitors
EP1581539A4 (en) Novel tyrosine kinase inhibitors
AU2003275282A8 (en) Novel tyrosine kinase inhibitors
AU2003254051A8 (en) Pyrazolopyrimidines as kinase inhibitors
EP1532133A4 (en) Nf-:b inhibitors
PL378116A1 (en) Heterocyclic kinase inhibitors
EP1651599A4 (en) Tyrosine kinase inhibitors
EP1496897A4 (en) Tyrosine kinase inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050530

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20050530

Extension state: LT

Payment date: 20050530

A4 Supplementary search report drawn up and despatched

Effective date: 20080424

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080501